SI1007024T1 - Delayed-release dosage forms of sertraline - Google Patents

Delayed-release dosage forms of sertraline

Info

Publication number
SI1007024T1
SI1007024T1 SI9830494T SI9830494T SI1007024T1 SI 1007024 T1 SI1007024 T1 SI 1007024T1 SI 9830494 T SI9830494 T SI 9830494T SI 9830494 T SI9830494 T SI 9830494T SI 1007024 T1 SI1007024 T1 SI 1007024T1
Authority
SI
Slovenia
Prior art keywords
sertraline
delayed
dosage forms
release dosage
release
Prior art date
Application number
SI9830494T
Other languages
English (en)
Slovenian (sl)
Inventor
William John Curatolo
Hylar Lewis Friedman
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21971681&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1007024(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of SI1007024T1 publication Critical patent/SI1007024T1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Addiction (AREA)
  • Gynecology & Obstetrics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI9830494T 1997-07-01 1998-06-16 Delayed-release dosage forms of sertraline SI1007024T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5149997P 1997-07-01 1997-07-01
PCT/IB1998/000937 WO1999001122A1 (fr) 1997-07-01 1998-06-16 Formes posologiques de sertraline, a action retardee
EP98923022A EP1007024B1 (fr) 1997-07-01 1998-06-16 Formes posologiques de sertraline, a action retardee

Publications (1)

Publication Number Publication Date
SI1007024T1 true SI1007024T1 (en) 2003-12-31

Family

ID=21971681

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9830494T SI1007024T1 (en) 1997-07-01 1998-06-16 Delayed-release dosage forms of sertraline

Country Status (41)

Country Link
EP (1) EP1007024B1 (fr)
JP (1) JP3786715B2 (fr)
KR (1) KR100369698B1 (fr)
CN (4) CN1151783C (fr)
AP (1) AP1199A (fr)
AR (1) AR038394A2 (fr)
AT (1) ATE245415T1 (fr)
AU (1) AU727152B2 (fr)
BG (1) BG64742B1 (fr)
BR (1) BR9809895A (fr)
CA (1) CA2290969C (fr)
DE (1) DE69816624T2 (fr)
DK (1) DK1007024T3 (fr)
DZ (1) DZ2547A1 (fr)
EA (1) EA001906B1 (fr)
ES (1) ES2202858T3 (fr)
GT (1) GT199800091A (fr)
HK (1) HK1027982A1 (fr)
HN (1) HN1998000099A (fr)
HR (1) HRP980376B1 (fr)
HU (1) HUP0301787A3 (fr)
ID (1) ID23187A (fr)
IL (2) IL152304A0 (fr)
IS (1) IS5267A (fr)
MA (1) MA24585A1 (fr)
NO (1) NO996519L (fr)
NZ (1) NZ501249A (fr)
OA (1) OA11247A (fr)
PA (1) PA8454201A1 (fr)
PE (1) PE84399A1 (fr)
PL (1) PL337799A1 (fr)
PT (1) PT1007024E (fr)
SI (1) SI1007024T1 (fr)
SK (1) SK173299A3 (fr)
TN (1) TNSN98122A1 (fr)
TR (1) TR199903295T2 (fr)
TW (1) TW575437B (fr)
UA (1) UA63953C2 (fr)
UY (1) UY25068A1 (fr)
WO (1) WO1999001122A1 (fr)
ZA (1) ZA985710B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1126826B3 (fr) 1998-11-02 2019-05-15 Alkermes Pharma Ireland Limited Composition de methylphenidate a liberation modifiee multiparticulaire
IE990406A1 (en) 1999-05-20 2000-12-27 Elan Corp Plc Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
CA2698347A1 (fr) * 1999-05-20 2000-11-30 Elan Pharma International Limited Preparations d'inhibiteurs specifiques du recaptage de la serotonine a liberation multiparticulaire regulee
IL148159A0 (en) 1999-09-03 2002-09-12 Lilly Co Eli Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
ES2168043B1 (es) * 1999-09-13 2003-04-01 Esteve Labor Dr Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
WO2001058429A1 (fr) * 2000-02-10 2001-08-16 Bpsi Holdings, Inc. Compositions utilisees pour former des revetements gastro-resistants acryliques
AP2001002264A0 (en) 2000-08-30 2001-09-30 Pfizer Prod Inc Sustained release formulations for growth hormone secretagogues.
US6482440B2 (en) * 2000-09-21 2002-11-19 Phase 2 Discovery, Inc. Long acting antidepressant microparticles
EP1377276B1 (fr) * 2001-04-10 2011-10-05 Sun Pharma Advanced Research Company Limited Composition a liberation par impulsion reglee dans le temps
CA2457385A1 (fr) * 2001-08-06 2003-02-20 Dr. Reddy's Laboratories Ltd. Preparation enterique de fluoxetine
GB0607534D0 (en) * 2006-04-13 2006-05-24 Univ London Pharmacy Colonic drug delivery formulation
EP2586429A1 (fr) * 2011-10-26 2013-05-01 Freund Pharmatec Ltd. Dispositif d'administration de médicaments à plusieurs unités pour libération pulsatile ou prolongée
CN108014087A (zh) * 2017-12-27 2018-05-11 江苏联环药业股份有限公司 一种盐酸舍曲林胶囊的制备方法
CN109432038A (zh) * 2018-12-28 2019-03-08 乐普制药科技有限公司 一种含有盐酸舍曲林的肠溶片剂及其制备方法
CN114129540B (zh) * 2021-11-19 2022-07-05 浙江维康药业股份有限公司 一种肝苏胶囊及其制作方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK150008C (da) * 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
US4803076A (en) * 1986-09-04 1989-02-07 Pfizer Inc. Controlled release device for an active substance
EP0357364B1 (fr) * 1988-08-30 1993-07-28 E.I. Du Pont De Nemours And Company Procédé pour le filage-éclair de torons de polymères secs à partir de film-fibrilles plexifilamentaires
IL91398A (en) * 1988-08-30 1994-05-30 Pfizer A device for the controlled release of pneumatic substances, including the active substance, surrounded by an asymmetric membrane
US4983401A (en) * 1989-05-22 1991-01-08 Kinaform Technology, Inc. Sustained release pharmaceutical preparations having pH controlled membrane coatings

Also Published As

Publication number Publication date
DK1007024T3 (da) 2003-11-17
AP1199A (en) 2003-08-28
TW575437B (en) 2004-02-11
EP1007024B1 (fr) 2003-07-23
WO1999001122A1 (fr) 1999-01-14
HK1027982A1 (en) 2001-02-02
SK173299A3 (en) 2000-11-07
OA11247A (en) 2002-11-19
HUP0301787A3 (en) 2005-04-28
TR199903295T2 (xx) 2000-08-21
MA24585A1 (fr) 1998-12-31
CN1151783C (zh) 2004-06-02
EA001906B1 (ru) 2001-10-22
HN1998000099A (es) 1998-10-22
TNSN98122A1 (fr) 2005-03-15
KR100369698B1 (ko) 2003-01-30
ZA985710B (en) 2000-01-10
IL133081A0 (en) 2001-03-19
AP9801278A0 (en) 1998-06-30
NZ501249A (en) 2001-06-29
PL337799A1 (en) 2000-09-11
PA8454201A1 (es) 2000-09-29
AU7545198A (en) 1999-01-25
PT1007024E (pt) 2003-11-28
AU727152B2 (en) 2000-12-07
EA199900965A1 (ru) 2000-08-28
NO996519D0 (no) 1999-12-28
HRP980376B1 (en) 2002-12-31
PE84399A1 (es) 1999-09-11
DE69816624T2 (de) 2004-02-19
CN1494899A (zh) 2004-05-12
ID23187A (id) 2000-03-23
UY25068A1 (es) 2000-12-29
CN1475208A (zh) 2004-02-18
AR038394A2 (es) 2005-01-12
IL133081A (en) 2005-09-25
ES2202858T3 (es) 2004-04-01
GT199800091A (es) 1999-12-21
IL152304A0 (en) 2003-05-29
DZ2547A1 (fr) 2003-02-08
HUP0301787A2 (hu) 2003-11-28
NO996519L (no) 2000-02-29
BG103916A (en) 2000-07-31
BG64742B1 (bg) 2006-02-28
BR9809895A (pt) 2000-08-01
KR20010013522A (ko) 2001-02-26
DE69816624D1 (de) 2003-08-28
UA63953C2 (uk) 2004-02-16
ATE245415T1 (de) 2003-08-15
CA2290969A1 (fr) 1999-01-14
CA2290969C (fr) 2004-02-17
EP1007024A1 (fr) 2000-06-14
JP2000513751A (ja) 2000-10-17
JP3786715B2 (ja) 2006-06-14
IS5267A (is) 1999-11-23
CN1261273A (zh) 2000-07-26
HRP980376A2 (en) 1999-04-30
CN1475209A (zh) 2004-02-18

Similar Documents

Publication Publication Date Title
IL133080A0 (en) Sertraline salts and sustained-release dosage forms of sertraline
GB2310601B (en) Paracetamol sustained-release formulation
SI0948541T1 (sl) PTHrP analogi
ZA983176B (en) Therapeutic compounds
IL120382A0 (en) Extended release formulation of venlafaxine hydrochloride
ZA987551B (en) Solid pharmaceutical dosage forms
IL152304A0 (en) Delayed-release dosage forms of sertraline
GB9512290D0 (en) Uses of polyhexanide
GB9413935D0 (en) Use of maramyl peptide compounds
AP9801279A0 (en) Encapsulated solution dosage forms of sertraline
PL338781A1 (en) Dosage form
GB9716345D0 (en) Therapeutic compounds
GB9716344D0 (en) Therapeutic compounds
GB9716347D0 (en) Therapeutic compounds
ZA985707B (en) Sertraline salts and sustained-release dosage forms of sertraline.
IL124387A0 (en) Preparation of 5-Methyleneoxazolines
GB2329384B (en) Preparation of 1-chloro-1-cyclopropylethene
SI0980241T1 (en) Gelatine encapsulated solution dosage forms of sertraline
GB9718683D0 (en) Novel dosage form
GB9704978D0 (en) Dosage forms
GB9719261D0 (en) Dosage forms
IL121488A0 (en) A pharmaceutical composition for the treatment of multiple sclerosis
GB9703750D0 (en) Treatment of haemorrhoids
GB9716111D0 (en) Therapeutic compounds
GB9705401D0 (en) Therapeutic compounds